

**Surname:** D'Ambrosio **Name:** Lorenzo

**E-mail:** lorenzo.dambrosio.md@gmail.com

### **Education**

- 31 May 2021 - Abilitazione Scientifica Nazionale (valid until 31 May 2030), Italian Ministry of University and Research
- January 2017: PhD in Biomedical Science and Oncology, University of Turin
- May 2015: Fellowship in Medical Oncology at the University of Turin. Grade: 70/70 cum laude and printing dignity.
- February 2010: Medical Board Certification, University of Turin, Italy
- July 2009: Degree in Medicine at the University of Turin. Grade: 110/110 cum laude and printing dignity.
- July 2003: High School Final Certificate, "Galileo Ferraris" Scientific Liceum of Turin. Grade:100/100

### **Work experience**

- April 2019 – present day: Attending Physician – Medical Oncology, Cardinal Massaia Hospital Asti
- October 2019 – present day: Board Member of the EORTC Soft Tissue and Bone Sarcoma Group as Young Oncologist
- May 2016 – April 2019: Consultant Medical Oncologist at the Istituto di Candiolo – Fondazione del Piemonte per l'Oncologia, IRCCS
- June 2015 - May 2018: Research Fellow at the University of Turin
- May 2010 - May 2015: Fellow in Medical Oncology at the University of Turin. Working place: Medical Oncology Istituto di Candiolo – Fondazione del Piemonte per l'Oncologia, IRCCS.
- May 2008 - July 2009: Intern at the Institute for Cancer Research and Treatment of Candiolo, Division of Medical Oncology.
- September 2003 - July 2009: Master Degree Course in Medicine at the University of Turin
- July 2003: High School Final Certificate, "Galileo Ferraris" Scientific Liceum of Turin. Grade:100/100

### **Research experience**

May 2010 - present day: involved as co-investigator or PI in conduction of phase I, II, III and IV clinical trials in GCP; retrospective or observational studies; planning and designing of phase I and II clinical trials in GCP; preclinical results evaluation; data collection, analysis and interpretation. Main research topic on soft tissue sarcomas, bone tumors, GIST, rare tumors and immunotherapy.

### **Languages**

Reading skills: Italian (mother tongue), English (excellent)

Writing skills: Italian (mother tongue), English (good)

Verbal skills: Italian (mother tongue), English (good)

### **Awards**

September 2010: "Optime" Award from "Unione Industriale di Torino" in collaboration with University of Turin

September 2018 Best Poster D-Day 2018 – University of Turin

November 2018 AIOM 2018 Sarcoma Award – AIOM

Turin, 20-Jan-2022

---

Date and place



---

Lorenzo D'Ambrosio MD PhD

## PUBLICATIONS

Papers

- Pignochino Y, Crisafulli G, Giordano G, Merlini A, Berrino E, Centomo ML, Chiabotto G, Brusco S, Basiricò M, Maldi E, Pisacane A, Leuci V, Sangiolo D, **D'Ambrosio L**, Aglietta M, Kasper B, Bardelli A, Grignani G. PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational Study. *Cancers (Basel)*. 2021 Dec 15;13(24):6295. doi: 10.3390/cancers13246295. PMID: 34944915; PMCID: PMC8699802.
- Giordano G, Merlini A, Ferrero G, Mesiano G, Fiorino E, Brusco S, Centomo ML, Leuci V, **D'Ambrosio L**, Aglietta M, Sangiolo D, Grignani G, Pignochino Y. EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma. *Cells*. 2021 Oct 26;10(11):2893. doi: 10.3390/cells10112893. PMID: 34831119; PMCID: PMC8616526.
- Nannini M, Rizzo A, Nigro MC, Vincenzi B, Mazzocca A, Grignani G, Merlini A, **D'Ambrosio L**, Tolomeo F, Badalamenti G, Incorvaia L, Bonasera A, Fumagalli E, Miliziano D, Ligorio F, Brunello A, Chiusole B, Gasperoni S, Novelli M, Pantaleo MA. Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study. *ESMO Open*. 2021 Aug;6(4):100222. doi: 10.1016/j.esmoop.2021.100222. Epub 2021 Aug 2. PMID: 34352702; PMCID: PMC8350191.
- Kantidakis G, Litière S, Neven A, Vinches M, Judson I, Schöffski P, Wardelmann E, Stacchiotti S, **D'Ambrosio L**, Marréaud S, van der Graaf WTA, Kasper B, Fiocco M, Gelderblom H. Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas. *Eur J Cancer*. 2021 Sep;154:253-268. doi: 10.1016/j.ejca.2021.06.025. Epub 2021 Jul 20. PMID: 34298376.
- Cannella R, Tabone E, Porrello G, Cappello G, Gozzo C, Incorvaia L, Grignani G, Merlini A, **D'Ambrosio L**, Badalamenti G, Regge D, Bartolotta TV. Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors. *Eur Radiol*. 2021 Apr 21. doi: 10.1007/s00330-021-07961-3. Epub ahead of print. PMID: 33881567.
- Carnevale-Schianca F, Caravelli D, Gallo S, Becco P, Paruzzo L, Poletto S, Polo A, Mangioni M, Salierno M, Berger M, Pessolano R, Saglio F, Gottardi D, Rota-Scalabrini D, Grignani G, Fizzotti M, Ferrero I, Frascione PMM, **D'Ambrosio L**, Gaidano V, Gammaitoni L, Sangiolo D, Saglietto A, Vassallo E, Cignetti A, Aglietta M, Fagioli F. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. *J Clin Med*. 2021 Mar 11;10(6):1173. doi: 10.3390/jcm10061173. PMID: 33799685
- Leuci Valeria, Donini Chiara, Grignani Giovanni, Rotolo Ramona, Mesiano Giulia, Fiorino Erika, Gammaitoni Loretta, **D'Ambrosio L**, Merlini Alessandra, Landoni Elisa, Medico Enzo, Capellero Sonia, Giraud Lidia, Cattaneo Giulia, Iaia Ilenia, Pignochino Ymera, Basirico Marco, Vigna Elisa, Pisacane Alberto, Fagioli Franca, Ferrone Soldano, Aglietta Massimo, Dotti Gianpietro, Sangiolo Dario. CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. *Clin Cancer Res*. 2020 Dec 1;26(23):6321-6334. doi: 10.1158/1078-0432.CCR-20-0357. Epub 2020 Sep 8. PMID: 32900797
- Martin-Broto J, Hindi N, Grignani G, Martinez-Trufero J, Redondo A, Valverde C, Stacchiotti S, Lopez-Pousa A, **D'Ambrosio L**, Gutierrez A, Perez-Vega H, Encinas-Tobajas V, de Alava E, Collini P, Peña-Chilet M, Dopazo J, Carrasco-Garcia I, Lopez-Alvarez M, Moura DS, Lopez-Martin JA. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. *J Immunother Cancer*. 2020 Nov;8(2):e001561. doi: 10.1136/jitc-2020-001561. PMID: 33203665
- Chiabotto G, Grignani G, Todorovic M, Martin V, Centomo ML, Prola E, Giordano G, Merlini A, Miglio U, Berrino E, Napione L, Isella C, Capozzi F, Basirico M, Marsero C, Gerardi I, Venesio T, Sangiolo D,

### Curriculum Vitae - D'AMBROSIO Lorenzo

Aglietta M, **D'Ambrosio L\***, Pignochino Y\*. (**co-last\***) Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights. *Cancers (Basel)*. 2020 Jun 10;12(6):1519. doi: 10.3390/cancers12061519. PMID: 32531992; PMCID: PMC7352822.

- Grosso F\*, **D'Ambrosio L\***, Zucchetti M, Ibrahim T, Tamberi S, Matteo C, Rulli E, Comandini D, Palmerini E, Baldi GG, DeCensi A, Bergaglio M, Marra D, Marchesi E, Siri G, D'Incalci M, Grignani G. (**\*co-first**) Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US Study) from the Italian Sarcoma Group. *Cancer*. 2020 Nov 1;126(21):4726-4734. doi: 10.1002/cncr.33120. Epub 2020 Aug 4. PMID: 32749681.
- Palmerini E, Setola E, Grignani G, **D'Ambrosio L\***, Comandone A, Righi A, Longhi A, Cesari M, Paioli A, Hakim R, Pierini M, Marchesi E, Vanel D, Pignochino Y, Donati DM, Picci P, Ferrari S. (2020). (**\*corresponding author**) High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series. *Cells*. 2020 Oct 31;9(11):2389. doi: 10.3390/cells9112389. PMID: 33142760
- **D'Ambrosio L**, Litière S, Stacchiotti S, Gronchi A. Reply to Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals. *Cancer*. 2020 Oct 15;126(20):4615-4616. doi: 10.1002/cncr.33110. Epub 2020 Aug 7. PMID: 32767667.
- **D'Ambrosio L**, Touati N, Blay JY, Grignani G, Flippot R, Czarnecka AM, Piperno-Neumann S, Martin-Broto J, Sanfilippo R, Katz D, Duffaud F, Vincenzi B, Stark DP, Mazzeo F, Tuchscherer A, Chevreau C, Sherriff J, Estival A, Litière S, Sents W, Ray-Coquard I, Tolomeo F, Le Cesne A, Rutkowski P, Stacchiotti S, Kasper B, Gelderblom H, Gronchi A; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *Cancer*. 2020 Jun 1;126(11):2637-2647. doi: 10.1002/cncr.32795. Epub 2020 Mar 4. PMID: 32129883.
- Grignani G, Merlini A, Sangiolo D, **D'Ambrosio L\***, Pignochino Y. (**\*corresponding author**). Delving into PARP inhibition from bench to bedside and back. *Pharmacol Ther*. 2020 Feb;206:107446. doi: 10.1016/j.pharmthera.2019.107446. Epub 2019 Nov 19. PMID: 31756364.
- Grignani G, D'Ambrosio L. Eribulin-based treatment in patients affected by sarcomas: a case series. *Future Oncol*. 2020 Jan;16(1s):1-3. doi: 10.2217/fo-2019-0601. Epub 2019 Dec 16. PMID: 31840540.
- **D'Ambrosio L**, Aglietta M, Grignani G. Preventing Venous Thromboembolism in Patients with Cancer. *N Engl J Med*. 2019 May 30;380(22):2180-2181. doi: 10.1056/NEJMc1904003. PMID: 31141644.
- Grignani G\*, **D'Ambrosio L\***, Pignochino Y, Palmerini E, Zucchetti M, Boccone P, Aliberti S, Stacchiotti S, Bertulli R, Piana R, Miano S, Toloineo F, Chiabotto G, Sangiolo D, Pisacane A, Dei Tos AP, Novara L, Bartolini A, Marchesi E, D'Incaici M, Bardelli A, Picci P, Ferrari S, Aglietta M. (**\*co-first**) Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. *Lancet Oncol*. 2018 Oct;19(10):1360-1371. doi: 10.1016/S1470-2045(18)30438-8. Epub 2018 Sep 11. PMID: 30217671.
- Mesiano G, Grignani G, Fiorino E, Leuci V, Rotolo R, **D'Ambrosio L**, Salfi C, Gammaitoni L, Giraudo L, Pisacane A, Butera S, Pignochino Y, Basirico M, Capozzi F, Sapino A, Aglietta M, Sangiolo D. Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy. *Oncoimmunology*. 2018 Aug 6;7(11):e1465161. doi: 10.1080/2162402X.2018.1465161. PMID: 30393581; PMCID: PMC6208452.
- Vincenzi B, Nannini M, Badalamenti G, Grignani G, Fumagalli E, Gasperoni S, **D'Ambrosio L**, Incorvaia L, Stellato M, Ceruso MS, Napolitano A, Valeri S, Santini D, Tonini G, Casali PG, Dei Tos AP, Pantaleo MA. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. *Ther Adv Med Oncol*. 2018 Aug 29;10:1758835918794623. doi: 10.1177/1758835918794623. PMID: 30181783
- Palmerini E, Jones RL, Setola E, Picci P, Marchesi E, Luksch R, Grignani G, Cesari M, Longhi A, Abate ME, Paioli A, Szucs Z, **D'Ambrosio L**, Scotlandi K, Fagioli F, Asaftei S, Ferrari S. Irinotecan and

### Curriculum Vitae - D'AMBROSIO Lorenzo

temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. *Acta Oncol.* 2018 Jul;57(7):958-964. doi: 10.1080/0284186X.2018.1449250. Epub 2018 Mar 13. PMID: 29533113.

- Tseng WW, Tsao-Wei DD, Callegaro D, Grignani G, **D'Ambrosio L**, Bonvalot S, Ethun CG, Cardona K, Mullen JT, Canter RJ, Mullinax JE, Gonzalez RJ, van Coevorden F, Albertsmeier M, Dhanireddy KK, Renne SL, Gronchi A. Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma. *Eur J Surg Oncol.* 2018 Jun;44(6):810-815. doi: 10.1016/j.ejso.2018.01.086. Epub 2018 Feb 5. PMID: 29452860.
- Donini C\*, **D'Ambrosio L\***, Grignani G, Aglietta M, Sangiolo D. (**\*co-first**) Next generation immune-checkpoints for cancer therapy. *J Thorac Dis.* 2018 May;10(Suppl 13):S1581-S1601. doi: 10.21037/jtd.2018.02.79. PMID: 29951308
- Leuci V, Casucci GM, Grignani G, Rotolo R, Rossotti U, Vigna E, Gammaitoni L, Mesiano G, Fiorino E, Donini C, Pisacane A, **D'Ambrosio L**, Pignochino Y, Aglietta M, Bondanza A, Sangiolo D. CD44v6 as innovative sarcoma target for CAR-redirectioned CIK cells. *Oncoimmunology.* 2018 Feb 15;7(5):e1423167. doi: 10.1080/2162402X.2017.1423167. PMID: 29721373
- Nannini M, Nigro MC, Vincenzi B, Fumagalli E, Grignani G, **D'Ambrosio L**, Badalamenti G, Incorvaia L, Bracci R, Gasperoni S, Saponara M, Gatto L, Indio V, Astolfi A, Di Scioscio V, Casali PG, Tonini G, Aglietta M, Russo A, Biasco G, Pantaleo MA. Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. *Ther Adv Med Oncol.* 2017 Dec;9(12):731-739. doi: 10.1177/1758834017742627. Epub 2017 Dec 19. PMID: 29449894
- **D'Ambrosio L**, Palesandro E, Boccone P, Tolomeo F, Miano S, Galizia D, Manca A, Chiara G, Bertotto I, Russo F, Campanella D, Venesio T, Sangiolo D, Pignochino Y, Siatis D, De Simone M, Ferrero A, Pisacane A, Dei Tos AP, Aliberti S, Aglietta M, Grignani G. Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. *Eur J Cancer.* 2017 Jun;78:122-132. doi: 10.1016/j.ejca.2017.03.025. Epub 2017 Apr 24. PMID: 28448856.
- **D'Ambrosio L**, Palesandro E, Moretti M, Pelosi G, Fabbri A, Schianca FC, Aglietta M, Grignani G. Alpha-fetoprotein elevation in NUT midline carcinoma: a case report. *BMC Cancer.* 2017 Apr 13;17(1):266. doi: 10.1186/s12885-017-3262-0. PMID: 28407756
- Pignochino Y, Capozzi F, **D'Ambrosio L**, Dell'Aglio C, Basirico M, Canta M, Lorenzato A, Lutati FV, Aliberti S, Palesandro E, Boccone P, Galizia D, Miano S, Chiabotto G, Napione L, Gammaitoni L, Sangiolo D, Benassi MS, Pasini B, Chiorino G, Aglietta M, Grignani G. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models. *Mol Cancer.* 2017 Apr 28;16(1):86. doi: 10.1186/s12943-017-0652-5. PMID: 28454547
- Longhi A, Bielack SS, Grimer R, Whelan J, Windhager R, Leithner A, Gronchi A, Biau D, Jutte P, Krieg AH, Klenke FM, Grignani G, Donati DM, Capanna R, Casanova J, Gerrand C, Bisogno G, Hecker-Nolting S, De Lisa M, **D'Ambrosio L**, Willegger M, Scoccianti G, Ferrari S. (2017). Extraskelletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients. *Eur J Cancer.* 2017 Mar;74:9-16. doi: 10.1016/j.ejca.2016.12.016. Epub 2017 Feb 3. PMID: 28167373.
- Carnevale-Schianca F, Caravelli D, Gallo S, Cocha V, **D'Ambrosio L**, Vassallo E, Fizzotti M, Nesi F, Gioeni L, Berger M, Polo A, Gammaitoni L, Becco P, Giraud L, Mangioni M, Sangiolo D, Grignani G, Rota-Scalabrini D, Sottile A, Fagioli F, Aglietta M. Post-Transplant Cyclophosphamide and Tacrolimus–Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. *Biol Blood Marrow Transplant.* 2017 Mar;23(3):459-466. doi: 10.1016/j.bbmt.2016.12.636. Epub 2016 Dec 27. PMID: 28039079.
- Marchesi E, Cagnazzo C, Quattrini I, Leopardi MP, Villa C, Grignani G, **D'Ambrosio L**, Stacchiotti S, Casali PG, Picci P. How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience. *Clin Sarcoma Res.* 2017 Feb 28;7:4. doi: 10.1186/s13569-017-0068-4. PMID: 28261443
- Grignani G, Palmerini E, Ferraresi V, **D'Ambrosio L**, Bertulli R, Asaftei S D, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, Capozzi F, Biagini R, Gambarotti M, Fagioli F, Casali P G, Picci P, Ferrari S, Aglietta M. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma

### Curriculum Vitae - D'AMBROSIO Lorenzo

progressing after standard treatment: a non-randomised phase 2 clinical trial. *Lancet Oncol.* 2015 Jan;16(1):98-107. doi: 10.1016/S1470-2045(14)71136-2. Epub 2014 Dec 11. PMID: 25498219.

- **D'Ambrosio L**, Aglietta M, Grignani G. Anticoagulation for Central Venous Catheters in Patients with Cancer. *N Engl J Med.* 2014 Oct 2;371(14):1362-3. doi: 10.1056/NEJMc1408861. PMID: 25271618
- Rota Scalabrini D, Caravelli D, Carnevale Schianca F, **D'Ambrosio L**, Tolomeo F, Boccone P, Manca A, De Rosa G, Nuzzo A, Aglietta M, Grignani G. Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature. *BMC Res Notes.* 2014 Aug 14;7:529. doi: 10.1186/1756-0500-7-529. PMID: 25125318
- Sangiolo D, Mesiano G, Gammaitoni L, Leuci V, Todorovic M, Giraudo L, Cammarata C, Dell'Aglio C, **D'Ambrosio L**, Pisacane A, Sarotto I, Miano S, Ferrero I, Carnevale-Schianca Fabrizio, Pignochino Ymera, Sassi F, Bertotti A, Piacibello W, Fagioli F, Aglietta M, Grignani G. Cytokine-Induced Killer Cells Eradicate Bone and Soft-Tissue Sarcomas. *Cancer Res.* 2014 Jan 1;74(1):119-29. doi: 10.1158/0008-5472.CAN-13-1559. Epub 2013 Dec 19. PMID: 24356422
- Pignochino Y, Dell'Aglio C, Basirico M, Capozzi F, Soster M, Marchio S, Bruno S, Gammaitoni L, Sangiolo D, Torchiano E, **D'Ambrosio L**, Fagioli F, Ferrari S, Alberghini M, Picci P, Aglietta M, Grignani G. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models. *Clin Cancer Res.* 2013 Apr 15;19(8):2117-31. doi: 10.1158/1078-0432.CCR-12-2293. Epub 2013 Feb 22. PMID: 23434734.
- Grignani G, Palmerini E, Dileo P, Asaftei S D, **D'Ambrosio L**, Pignochino Y, Mercuri M, Picci P, Fagioli F, Casali P G, Ferrari S, Aglietta M. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. *Ann Oncol.* 2012 Feb;23(2):508-16. doi: 10.1093/annonc/mdr151. Epub 2011 Apr 28. PMID: 21527590.
- Carnevale-Schianca F, Gallo S, Rota-Scalabrini D, Sangiolo D, Fizzotti M, Caravelli D, Capaldi A, Anselmetti G, Palesandro E, **D'Ambrosio L**, Coha V, Obert R, Aglietta M, Grignani G. Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity? *J Clin Oncol.* 2011 Aug 20;29(24):e691-3. doi: 10.1200/JCO.2011.35.6733. Epub 2011 Jun 27. PMID: 21709191.

### **Book Chapters**

- Chapter 42 - Immunological and Genetic Biomarkers of Sarcomas: Implication for Future Treatment Strategies. Authors: Lorenzo D'Ambrosio, Dario Sangiolo, Alessandra Merlini, Giovanni Grignani, Massimo Aglietta. Book: Oncogenomics. Editor(s): Franco Dammacco, Franco Silvestri. Academic Press, 2019, Pages 591-608. ISBN 9780128117859. <https://doi.org/10.1016/B978-0-12-811785-9.00042-9>. <http://www.sciencedirect.com/science/article/pii/B9780128117859000429>. First Publication 30-Oct-2018
- Capitolo 3.15. Applicazioni cliniche: prospettive future. Autore: Lorenzo D'Ambrosio. Libro: Immunoncologia: dalle prove sperimentali alla pratica clinica. Editori: Marco Merlano, Massimo Aglietta, Dario Sangiolo. Attività editoriali Accademia Nazionale di Medicina, Forum Service Editore. 2017. pag 155-163. ISBN 978-88-89620-91-5
- Capitolo 4: Diagnosi Differenziale. Giovanni Grignani, Lorenzo D'Ambrosio, Massimo Aglietta. Libro: I Sarcomi dei Tessuti Molli. Editori: Alessandro Comandone, Sandro Barni. Pensiero Scientifico Editore 2011, 1<sup>a</sup> edizione